Johnson & Johnson $JNJ Position Lessened by Moody National Bank Trust Division

Moody National Bank Trust Division lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 9.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,355 shares of the company’s stock after selling 2,590 shares during the quarter. Moody National Bank Trust Division’s holdings in Johnson & Johnson were worth $6,712,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Outlook Capital Management LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter worth about $28,000. Matrix Trust Co raised its stake in Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after buying an additional 54 shares in the last quarter. Hyposwiss Advisors SA bought a new position in Johnson & Johnson in the fourth quarter worth about $42,000. Montgomery Financial Services LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at approximately $43,000. Finally, Polaris Financial Partners bought a new stake in Johnson & Johnson during the 3rd quarter valued at approximately $56,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.8%

Shares of NYSE JNJ traded up $1.92 during midday trading on Tuesday, hitting $254.85. The stock had a trading volume of 5,660,663 shares, compared to its average volume of 7,994,485. The business’s 50 day moving average is $266.10 and its 200-day moving average is $248.51. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52 week low of $182.94 and a 52 week high of $281.07. The company has a market cap of $614.17 billion, a P/E ratio of 29.53, a PEG ratio of 2.52 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. During the same quarter in the prior year, the business earned $2.77 EPS. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, analysts predict that Johnson & Johnson will post 11.54 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend was Tuesday, August 25th. Johnson & Johnson’s payout ratio is presently 62.11%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction on Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,779,963.81. This trade represents a 50.06% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 87,569 shares of company stock valued at $23,064,544 in the last 90 days. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: RBC Capital Markets said accelerating performance in J&J’s Innovative Medicine segment is offsetting persistent MedTech headwinds. The assessment supports the view that new drug launches and portfolio diversification can help sustain growth. Johnson & Johnson’s Innovative Medicines Momentum Offsets MedTech Headwinds
• Positive Sentiment: Analyst comparisons with Pfizer continue to favor J&J’s diversified portfolio, sales growth and new product pipeline, despite Pfizer’s lower valuation and higher dividend yield. Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
• Positive Sentiment: J&J remains attractive to income-oriented and defensive investors because healthcare demand is expected to remain relatively resilient during an economic downturn. Its long-term dividend reliability is also being highlighted in comparisons with Procter & Gamble. Looking for a Dividend Stock That Can Weather a Downturn?
• Neutral Sentiment: CEO Joaquin Duato said artificial intelligence should be embraced as a “force multiplier.” The comments point to potential long-term productivity and innovation benefits, but provide no near-term earnings update. Johnson & Johnson CEO Says AI Has to Be Embraced
• Negative Sentiment: MedTech’s rebound is uncertain after a second-quarter slowdown. Abiomed-related and broader competitive pressures could weigh on results, although Vision, Orthopedics and Surgery may improve in the second half. Can J&J’s MedTech Business Rebound in Q3?
• Negative Sentiment: Investors remain focused on an estimated $4 billion patent cliff in 2027. The need to replace that revenue stream could matter more than a modest quarterly earnings beat and is contributing to recent caution ahead of the report. Why a $4 Billion 2027 Patent Cliff Matters

Wall Street Analyst Weigh In

JNJ has been the subject of several research reports. Raymond James Financial set a $280.00 target price on Johnson & Johnson in a research report on Monday, August 3rd. Freedom Capital raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 16th. HSBC increased their price objective on Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. JPMorgan Chase & Co. boosted their target price on shares of Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a report on Tuesday, September 29th. Finally, Morgan Stanley upped their target price on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an “overweight” rating in a research report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $276.22.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.